Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex
03 mai 2022 09h17 HE
|
Qualigen Therapeutics, Inc.
Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs,” a Rising Global Health Crisis CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Qualigen...
Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President
29 avr. 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference
12 avr. 2022 10h15 HE
|
Qualigen Therapeutics, Inc.
Data Highlights In Vivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc....
Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®
05 avr. 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results
01 avr. 2022 08h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302
30 mars 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference
22 mars 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
Abstracts Review Positive In vivo Data and the Potential Mechanism of Action for QN-302 in Pancreatic and Prostate Cancers CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Qualigen...
Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program
15 mars 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders
22 févr. 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Data from Qualigen Therapeutics’ Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference
15 févr. 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
Posters to be Presented During the In-Person Conference Being Held April 8-13, 2022 in New Orleans CARLSBAD, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq:...